LTPB2 acts as a prognostic factor and promotes progression of cervical adenocarcinoma.
Latent transforming growth factor-beta-1 binding protein-2 (LTBP-2) is a member of the fibrillin/LTBP super family of extracellular matrix proteins, found to be overexpressed in certain malignant tumors. However, the clinical significance and biological role of LTBP-2 in cervical adenocarcinoma has remains unclear. We found that the expression of LTBP2 was higher in cervical adenocarcinoma than in normal cervical epithelial tissue as assessed by immunohistochemistry. Expression of LTBP2 is related to clinical stage, cervical tumor size, depth of cervical stromal invasion and lymph node metastasis. Knockdown of LTBP2 expression can inhibit the proliferation and migration of HeLa cells. Moreover, LTBP2 knockdown affected multiple tumor-related pathway genes including: the MAPK signaling pathway, the PI3K-AKT signaling pathway, receptor tyrosine kinase signaling and the P53 pathway. Taken together, this work suggests that LTBP2 may promote the development of cervical adenocarcinoma and serve as a prognostic factor in the clinical evaluation of patients with cervical adenocarcinoma. Our findings provide a new strategy for the diagnosis and treatment of cervical adenocarcinoma.
Obstetrics and Gynecology Hospital, Fudan University Shanghai 200011, PR China ; Changzhou Maternal and Child Health Care Hospital 213003, Jiangsu, PR China ; Department of Obstetrics and Gynecology of Shanghai Medical College, Fudan University Shanghai 200032, PR China ; Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases Shanghai 200011, PR China ; Cancer Institute, Fudan University Shanghai Cancer Center Shanghai 200032, PR China ; Institutes of Biomedical Sciences, Fudan University Shanghai 200032, PR China.
Yuan
Y
Ren
Department of Obstetrics and Gynecology, Fengxian Hospital, Southern Medical University Shanghai 201499, PR China.
Huan
H
Lu
Changzhou Maternal and Child Health Care Hospital 213003, Jiangsu, PR China.
Danmei
D
Zhao
Changzhou Maternal and Child Health Care Hospital 213003, Jiangsu, PR China.
Yangjun
Y
Ou
Changzhou Maternal and Child Health Care Hospital 213003, Jiangsu, PR China.
Kang
K
Yu
Changzhou Maternal and Child Health Care Hospital 213003, Jiangsu, PR China.
Jiandong
J
Gu
Changzhou Maternal and Child Health Care Hospital 213003, Jiangsu, PR China.
Li
L
Wang
State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine Shanghai 200240, PR China.
Shuheng
S
Jiang
Obstetrics and Gynecology Hospital, Fudan University Shanghai 200011, PR China ; Department of Obstetrics and Gynecology of Shanghai Medical College, Fudan University Shanghai 200032, PR China ; Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases Shanghai 200011, PR China ; Cancer Institute, Fudan University Shanghai Cancer Center Shanghai 200032, PR China ; Institutes of Biomedical Sciences, Fudan University Shanghai 200032, PR China.
Mo
M
Chen
Department of Obstetrics and Gynecology, Fengxian Hospital, Southern Medical University Shanghai 201499, PR China.
Jinghao
J
Wang
Department of Obstetrics and Gynecology, Fengxian Hospital, Southern Medical University Shanghai 201499, PR China.
Rong
R
Zhang
Obstetrics and Gynecology Hospital, Fudan University Shanghai 200011, PR China ; Department of Obstetrics and Gynecology of Shanghai Medical College, Fudan University Shanghai 200032, PR China ; Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases Shanghai 200011, PR China ; Cancer Institute, Fudan University Shanghai Cancer Center Shanghai 200032, PR China ; Institutes of Biomedical Sciences, Fudan University Shanghai 200032, PR China.
Congjian
C
Xu
LTPB2; cervical adenocarcinoma; prognostic factor